Treatment Resistant Depression (TRD): epidemiology, clinic, burden and treatment

75.2K

views

202

authors

23

articles

Treatment Resistant Depression (TRD): epidemiology, clinic, burden and treatment

75.2K

views

202

authors

23

articles

Editorial

18 March 2025

Editorial: Treatment resistant depression (TRD): epidemiology, clinic, burden and treatment

Andrea Fiorillo

,

Koen Demyttenaere

,

Vassilis Martiadis

and

Giovanni Martinotti

1,065 views

0 citations

Editors

4

Vassilis Martiadis

Asl Napoli 1 Centro, Department of Mental Health

Koen Demyttenaere

Giovanni Martinotti

University of Studies G. d'Annunzio Chieti and Pescara

Andrea Fiorillo

University of Campania Luigi Vanvitelli

Impact

Fetching...

About

Treatment Resistant Depression (TRD), in both unipolar and bipolar features, is a source of suffering for patients and a challenging topic for clinicians. Moreover, it has become time-consuming and financially impactful for health systems. TRD prevalence may vary among different countries and in different sample studies ranging from 30- to 40 % of patients treated with antidepressants; less is known about resistance in bipolar depression that may be further more pervasive and difficult to treat. Treatment-resistance is impactful for patients, caregivers and families, increasing disability and worsening quality of life. Treatment options may vary from traditional association and augmentations strategies to psychotherapy and to brain stimulation therapies (ECT, TMS, VNS). Recently, new pharmacological approaches have been developed focusing on psychedelic-derived drugs (ketamine, esketamine, psylocibin), providing clinicians with new treatment choices.

The aim of this Research Topic is to collect recent advances in TRD field from clinical, epidemiological, quality of life and burden aspects to traditional and novel treatment strategies. Original Research, Review, Case Reports, Perspective and Hypothesis & Theory studies are welcomed on the following topics:

- Clinical definition and characterization of unipolar and/or bipolar TRD

- Epidemiological data, patients quality of life and family burden, health care costs of unipolar and/or bipolar TRD

- TRD pharmacological treatment options, ranging from traditional strategies to novel psychedelic-derived drug approaches (ketamine, esketamine, psylocibin)

- Psychotherapy interventions

- Brain Stimulating Therapies (ECT, TMS, VNS)

These may considered only examples of desirable papers welcome in this research topic, but every type of contribution aiming to the characterization and clarification of TRD in its multiple aspects is welcome.

Treatment Resistant Depression (TRD), in both unipolar and bipolar features, is a source of suffering for patients and a challenging topic for clinicians. Moreover, it has become time-consuming and financially impactful for health systems. TRD prevalence may vary among different countries and in different sample studies ranging from 30- to 40 % of patients treated with antidepressants; less is known about resistance in bipolar depression that may be further more pervasive and difficult to treat. Treatment-resistance is impactful for patients, caregivers and families, increasing disability and worsening quality of life. Treatment options may vary from traditional association and augmentations strategies to psychotherapy and to brain stimulation therapies (ECT, TMS, VNS). Recently, new pharmacological approaches have been developed focusing on psychedelic-derived drugs (ketamine, esketamine, psylocibin), providing clinicians with new treatment choices.

The aim of this Research Topic is to collect recent advances in TRD field from clinical, epidemiological, quality of life and burden aspects to traditional and novel treatment strategies. Original Research, Review, Case Reports, Perspective and Hypothesis & Theory studies are welcomed on the following topics:

- Clinical definition and characterization of unipolar and/or bipolar TRD

- Epidemiological data, patients quality of life and family burden, health care costs of unipolar and/or bipolar TRD

- TRD pharmacological treatment options, ranging from traditional strategies to novel psychedelic-derived drug approaches (ketamine, esketamine, psylocibin)

- Psychotherapy interventions

- Brain Stimulating Therapies (ECT, TMS, VNS)

These may considered only examples of desirable papers welcome in this research topic, but every type of contribution aiming to the characterization and clarification of TRD in its multiple aspects is welcome.

Download ebook

Share

Editors

Vassilis Martiadis

Asl Napoli 1 Centro, Department of Mental Health

Koen Demyttenaere

Giovanni Martinotti

University of Studies G. d'Annunzio Chieti and Pescara

Andrea Fiorillo

University of Campania Luigi Vanvitelli

Impact

75,151 Total views

53,191 Article views

19,886 Article downloads

2,074 Topic views

Published In

Journal Thumbnail

Frontiers in Psychiatry

Mood Disorders, Neurostimulation

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic